Duska noted that the PD-L1 inhibitor pembrolizumab has shown efficacy in the treatment of recurrent or metastatic cervical ...

Rua Dr. Diogo de Faria, 1087 – 9º andar – Vila Clementino 04037-003 São Paulo/SP - Brasil E-mail: [email protected] ...

Piper Sandler upgrades Myriad Genetics to Overweight, citing stock stabilization and new leadership. The firm raises its ...

Myriad Genetics (MYGN) stock was upgraded to Overweight by Piper Sandler, citing a balanced risk-reward set up for its beaten ...

Short sellers have been increasing their bets, with short interest now accounting for 6.1% of the stock's available float.

Fintel reports that on March 12, 2025, Piper Sandler upgraded their outlook for Myriad Genetics (NasdaqGS:MYGN) from Neutral ...

Piper Sandler upgraded Myriad Genetics (MYGN) to Overweight from Neutral with a price target of $12.50, up from $11.50. The stock is down more ...

Morgan Stanley lowered the firm’s price target on Myriad Genetics (MYGN) to $16 from $21 and keeps an Equal Weight rating on the shares after ...

Genetic tests appeal to our sense of belonging and storytelling Adam Rutherford Unlike AncestryDNA, a competitor that stuck to genealogy, 23andMe also provided health reports, eventually ...

Whenever we spoke, there was something medically wrong,” the pal said of the “Gossip Girl” star’s health “curveballs.” ...

Myriad Genetics (NASDAQ:MYGN – Get Free Report) had its price objective decreased by Bank of America from $13.00 to $11.00 in a research report issued to clients and investors on Monday,Benzinga ...